Mettler-Toledo International Inc. (MTD) AI Stock Analysis

Mettler-Toledo International Inc. manufactures and markets precision instruments and services worldwide across five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. Its laboratory instrument lineup includes balances, titrators, pH meters, thermal analysis systems, and analytical tools supported by the LabX software platform. For industrial clients, the company supplies weighing instruments, automatic dimensional measurement solutions, vehicle scales, and product inspection systems like metal detection and x-ray devices. It also offers networked and stand-alone retail scales alongside packaging solutions, serving life sciences, food and beverage, chemical, logistics, and academic customers.

Between FY2021 and FY2025, revenue grew from $3.72B to $4.03B, representing a 5-year CAGR of 5.5% from FY2020 through FY2025. Annual revenue contracted 3.4% in FY2023 before expanding 2.2% in FY2024 and 4.0% in FY2025. Gross margin expanded from 56.7% in FY2021 to 59.4% in FY2025, while operating margin shifted from 26.8% to 27.8% over the same period. Annual net income rose from $769.0M in FY2021 to $869.2M in FY2025, with EPS increasing from $33.91 to $42.79. In the latest quarter ended June 30, 2026, quarterly revenue increased 4.5% year-over-year, and quarterly earnings grew 18.3% year-over-year.

As of June 30, 2026, Mettler-Toledo held $51.4M in cash and short-term investments against total debt of $2.11B, resulting in net debt of $2.06B. Shareholders' equity stood at $12.8M, yielding a current ratio of 1.12 and a debt-to-equity ratio of 164.70. Total assets were $3.67B. During FY2025, the company generated $955.8M in operating cash flow and $848.6M in free cash flow. Capital expenditures totaled $107.1M, and share buybacks reached $800.0M, contributing to a 13.2% decline in share count over 5 years.

At $1622.29, Mettler-Toledo trades at a trailing P/E of 36.6x and a forward P/E of 28.5x, compared to medians of 27.2x and 16.5x for the median of its S&P 500 Healthcare peers. Its EV/EBITDA of 24.6x and price-to-sales of 7.9x also exceed the peer group medians of 15.0x and 3.4x, respectively. The stock gained 19.3% over the past 1 year, outperforming the SPY return of 16.8%. Over a 5-year period, however, the stock returned 14.4% compared to an 83.0% gain for the S&P 500 benchmark.

Wall Street coverage includes 4 Strong Buy, 1 Buy, 7 Hold, 1 Sell, and 1 Strong Sell ratings. The mean price target is $1529.46, representing a 5.7% discount to the last close of $1622.29. Analysts estimate full-year revenue of $4.24B and EPS of $47.35 for the year ending December 31, 2026, reflecting 10.8% EPS growth. For the following fiscal year, 14 analysts expect EPS of $51.76 on revenue of $4.44B. The company beat EPS estimates in each of the last 4 quarters, with its next earnings report scheduled for November 5, 2026.

This page is an AI-written research summary of Mettler-Toledo International Inc. (MTD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MTD income statement, MTD balance sheet, MTD key metrics, MTD analyst forecast, MTD chart. See the MTD stock overview for the latest quote and news.